Zhiqiang Ku

7PUBLICATIONS

49CO-AUTHORS

Predictive and prognostic markersTumour immunologyMolecular, biological, and multi-scale communicationsMolecular targetsBiomaterials

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (7)

Sort by Publication Date:

|Jun 03, 2026

Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses in KRAS-mutant non-small cell lung cancer.

|Apr 03, 2026

Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer.

Xiaoye Liu, Ryan Huang, Zhiqiang Ku

|Nov 27, 2025

Author Correction: Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.

Zhiqiang Ku, Xuping Xie, Paul R Hinton

|Apr 26, 2023

Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L.

Christopher J LaFargue, Paola Amero, Kyunghee Noh

|Sep 22, 2022

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth.

Zhiqiang Ku, Xuping Xie, Jianqing Lin

|Nov 24, 2021

The N501Y spike substitution enhances SARS-CoV-2 infection and transmission.

Yang Liu, Jianying Liu, Kenneth S Plante

Pageof 2

Frequent Collaborators

Zhiqiang An

Ningyan Zhang

Xuping Xie

Vineet D Menachery

Pei-Yong Shi

Paul R Hinton

Bruce A Keyt

Stephen F Carroll

Kenneth S Plante

Jessica A Plante

Frequent Collaborators

Zhiqiang An

Ningyan Zhang

Xuping Xie

Vineet D Menachery